<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30390395</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>59</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Muscle &amp; nerve</Title>
          <ISOAbbreviation>Muscle Nerve</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Open-label trial of ranolazine for the treatment of paramyotonia congenita.</ArticleTitle>
        <Pagination>
          <StartPage>240</StartPage>
          <EndPage>243</EndPage>
          <MedlinePgn>240-243</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.26372</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION">Paramyotonia congenita (PMC) is a nondystrophic myotonic disorder that is believed to be caused by a defect in Na<sub>v</sub> 1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies are lacking.</AbstractText>
          <AbstractText Label="METHODS">We conducted an open-label, single-center trial of ranolazine to evaluate efficacy and tolerability in patients with PMC. Subjective symptoms of stiffness, weakness, and pain as well as clinical and electrical myotonia were evaluated. Baseline measures were compared with those after 4 weeks of treatment with ranolazine.</AbstractText>
          <AbstractText Label="RESULTS">Ranolazine was tolerated well without any serious adverse events. Both subjective symptoms and clinical myotonia were significantly improved. Duration of myotonia was reduced according to electromyography, but this change was not statistically significant in all tested muscles.</AbstractText>
          <AbstractText Label="DISCUSSION">Our findings support the use of ranolazine as a treatment for myotonia in PMC and suggest that a randomized, placebo-controlled trial is warranted. Muscle Nerve 59:240-243, 2019.</AbstractText>
          <CopyrightInformation>Â© 2018 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lorusso</LastName>
            <ForeName>Samantha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kline</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bartlett</LastName>
            <ForeName>Amy</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Freimer</LastName>
            <ForeName>Miriam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Agriesti</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hawash</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rich</LastName>
            <ForeName>Mark M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kissel</LastName>
            <ForeName>John T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>David Arnold</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02251457</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>UL1 TR001070</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <Agency>Gilead Sciences</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>378033</GrantID>
            <Agency>Muscular Dystrophy Association</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <Agency>Ohio State University</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <Agency>Center for Clinical and Translational Science</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Muscle Nerve</MedlineTA>
        <NlmUniqueID>7803146</NlmUniqueID>
        <ISSNLinking>0148-639X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>A6IEZ5M406</RegistryNumber>
          <NameOfSubstance UI="D000069458">Ranolazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020967" MajorTopicYN="N">Myotonic Disorders</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069458" MajorTopicYN="N">Ranolazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016750" MajorTopicYN="N">Stiff-Person Syndrome</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">channelopathy</Keyword>
        <Keyword MajorTopicYN="Y">electromyography</Keyword>
        <Keyword MajorTopicYN="Y">myotonia</Keyword>
        <Keyword MajorTopicYN="Y">paramyotonia</Keyword>
        <Keyword MajorTopicYN="Y">ranolazine</Keyword>
        <Keyword MajorTopicYN="Y">stiffness</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30390395</ArticleId>
        <ArticleId IdType="mid">NIHMS999006</ArticleId>
        <ArticleId IdType="pmc">PMC6340713</ArticleId>
        <ArticleId IdType="doi">10.1002/mus.26372</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol
2015;5(2):761â790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754081</ArticleId>
            <ArticleId IdType="pubmed">25880512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayward LJ, Brown RH Jr., Cannon SC. Slow inactivation differs among mutant Na channels associated with myotonia and periodic paralysis. Biophysical journal
1997;72(3):1204â1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1184504</ArticleId>
            <ArticleId IdType="pubmed">9138567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Statland JM, Bundy BN, Wang Y, et al.
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: A randomized controlled trial. JAMA
2012;308(13):1357â1365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3564227</ArticleId>
            <ArticleId IdType="pubmed">23032552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain
2017;140(9):2295â2305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29050397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>KwieciÅski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurologica Scandinavica
1992;86(4):371â375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1455983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novak KR, Norman J, Mitchell JR, Pinter MJ, Rich MM. Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Annals of neurology
2015;77(2):320â332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4315705</ArticleId>
            <ArticleId IdType="pubmed">25515836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Bizri N, Kahlig KM, Shyrock JC, George Alfred L. Jr., Belardinelli L, Rajamani S. Ranolazine block of human Nav1.4 sodium channels and paramyotonia congenita mutants. Channels
2011;5(2):161â172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21317558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Podsiadlo D, Richardson S. The timed âUp &amp; Goâ: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc
1991;39(2):142â148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1991946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, Willer JC, Tabti N, Fontaine B. Electromyography guides toward subgroups of mutations in muscle channelopathies. Annals of neurology
2004;56(5):650â661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15389891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold WD, Kline D, Sanderson A, Hawash AA, Bartlett A, Novak KR, Rich MM, Kissel JT. Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology
2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5562961</ArticleId>
            <ArticleId IdType="pubmed">28710329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Bizri N, Kahlig KM, Shyrock JC, George AL Jr., Belardinelli L, Rajamani S. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants. Channels (Austin)
2011;5(2):161â172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21317558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipicky RJ, Bryant SH, Salmon JH. Cable parameters, sodium, potassium, chloride, and water content, and potassium efflux in isolated external intercostal muscle of normal volunteers and patients with myotonia congenita. Journal of Clinical Investigation
1971;50(10):2091â2103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC292143</ArticleId>
            <ArticleId IdType="pubmed">4940295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, Zoll B, Lehmann-Horn F, Grzeschik KH, Jentsch TJ. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science
1992;257(5071):797â800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1379744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinmeyer K, Klocke R, Ortland C, Gronemeier M, Jockusch H, Grunder S, Jentsch TJ. Inactivation of muscle chloride channel by transposon insertion in myotonic mice. Nature
1991;354(6351):304â308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1659665</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
